Download Files:
Products Details
Product Description
– BMS-639623 is a potent and orally activeCCR3 antagonist with an IC50 of 0.3 nM. BMS-639623 picomolar inhibition potency against eosinophil chemotaxis (IC50=38 pM). BMS-639623 can be used for the research of asthma[1].
Web ID
– HY-120629
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C25H32FN7O2
References
– [1]Santella JB 3rd, et al. From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis. Bioorg Med Chem Lett. 2008;18(2):576-585.
CAS Number
– 675122-44-8
Molecular Weight
– 481.57
SMILES
– O=C(NC1=CC=CC(C2=NN=NN2C)=C1)N[C@H](C)[C@@H](O)CN3C[C@H](CC4=CC=C(F)C=C4)CCC3
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– CCR
Isoform
– CCR3
Pathway
– GPCR/G Protein;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
